Wanbury Q3 FY26 PAT up 13x; revenue up 22% Y-o
WANBURY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.3 pts less than Nifty Microcap 250 and 6.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Wanbury reported strong Q3 FY26 results. Revenue rose 21.7% Y-o-Y to Rs. 162.4 crore; 9M FY26 revenue grew 13.6% to Rs. 485.7 crore. EBITDA surged 81.7% to Rs. 26.9 crore with margin expanding to 16.5% from 11.0%. PAT jumped to Rs. 15.8 crore from Rs. 1.2 crore, while 9M PAT rose 332.5% to Rs. 44.4 crore. Growth was driven by higher API volumes, better capacity use, cost optimization, and lower finance costs.
Sharp profit growth and margin expansion reflect strong operational turnaround, likely positive for stock sentiment.